Critical Contrast: Biogen (BIIB) and Seattle Genetics (SGEN)
Biogen (NASDAQ: SGEN) and Seattle Genetics (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
This is a breakdown of current ratings and recommmendations for Biogen and Seattle Genetics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Biogen and Seattle Genetics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biogen||$12.27 billion||5.67||$2.54 billion||$21.81||15.84|
|Seattle Genetics||$482.25 million||25.60||-$125.53 million||($0.88)||-88.36|
Biogen has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
This table compares Biogen and Seattle Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Biogen has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Seattle Genetics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
Institutional and Insider Ownership
87.4% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 33.8% of Seattle Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biogen beats Seattle Genetics on 11 of the 14 factors compared between the two stocks.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
About Seattle Genetics
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.